- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Contemporary Guidelines for CRM Conditions
Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.
EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity
EP: 2.Strategies for Prevention and Screening of CRM Conditions
EP: 3.The Link Between Obesity and CRM Conditions
EP: 4.Challenges in Managing Co-Morbid CRM Conditions
EP: 5.Contemporary Guidelines for CRM Conditions
EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions
EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions
EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM
EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines
EP: 10.Care Coordination for High-Risk CRM Patients
EP: 11.Takeaways from the UH CINEMA Program
EP: 12.Exploring the Kidney-CHAMP Study
EP: 13.Insights from the COORDINATE-Diabetes Trial
EP: 14.Coordinating Initiatives to Enhance CRM Care
EP: 15.Implementing CRM Learnings and Utilization of Telehealth
Video content above is prompted by the following:
- How do guidelines from professional organizations, including ACC, AHA, ADA, KDIGO, ACE, and DCRMi, address the management and interconnectivity of CRM conditions?
- How have these guidelines evolved in recent years? What are the notable guideline updates in recent years?
- What impact have these guidelines had on the treatment outcomes of patients with CRM conditions?
- What gaps are there in these guidelines regarding the management of CRM conditions?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases
January 28th 2025First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
Read More
FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
January 27th 2025The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.
Read More
